Chimeric Therapeutics is a clinical-stage cell therapy company with a focus on discovering, developing and commercialising novel cell therapies with the most curative potential for patients.
Chimeric Therapeutics is a clinical-stage cell therapy company with a focus on discovering, developing and commercialising novel cell therapies with the most curative potential for patients.
| Rank | Company | 1 Yr | 5 Yr |
|---|---|---|---|
| 1615th | Albright Metals | -75.07% | -44.87% |
| 1616th | Bioxyne | -75.44% | -18.53% |
| 1617th | Chimeric Therapeutics | -75.74% | -67.47% |
| 1618th | Conico | -76.47% | -64.19% |
| 1619th | PainChek | -76.61% | -28.86% |
|
NEW ROLE: Rebecca McQualter, | 02 Dec 2024 |
| NEW ROLE: Phillip Hains, Chief Financial Officer, Joint Company Secretary, Non Executive Director | 17 Jul 2024 | |
|
NEW ROLE: Eric Sullivan, Non-Executive Director | 17 Jul 2024 |
|
NEWS: Tagged in Chimeric drug declares war on deadly pancreatic cancer | 23 Nov 2023 |
|
NEWS: Tagged in Chimeric set to flick switch on clinical leukaemia trial | 20 Nov 2023 |
|
NEW ROLE: Jason Litten, | 06 Nov 2023 |
|
NEWS: Tagged in Chimeric steps up fight against deadliest brain cancer | 02 Nov 2023 |
|
NEWS: Tagged in FDA green-lights Chimeric gastrointestinal cancer drug trials | 31 Oct 2023 |
|
NEWS: Tagged in Brain cancer survival hopes lifted in Chimeric trials | 23 Oct 2023 |
Access to our data for Chimeric Therapeutics is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Chimeric Therapeutics is included in 1 list - Public Companies - non WA.
For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.